Volume | 1,314,619 |
|
|||||
News | - | ||||||
Day High | 1.79 | Low High |
|||||
Day Low | 1.6301 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioVie Inc | BIVI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.74 | 1.6301 | 1.79 | 1.68 | 1.80 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,951 | 1,314,619 | $ 1.70 | $ 2,234,182 | - | 1.50 - 14.38 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:56:45 | 50 | $ 1.75 | USD |
BioVie Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
64.54M | 37.74M | - | 0 | -50.26M | -1.33 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioVie News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIVI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.99 | 5.654 | 1.50 | 2.41 | 2,700,390 | -3.30 | -66.13% |
1 Month | 4.45 | 5.82 | 1.50 | 3.08 | 1,245,181 | -2.76 | -62.02% |
3 Months | 3.27 | 5.82 | 1.50 | 3.29 | 685,554 | -1.58 | -48.32% |
6 Months | 5.94 | 6.45 | 1.50 | 3.67 | 440,345 | -4.25 | -71.55% |
1 Year | 6.75 | 14.38 | 1.50 | 6.25 | 591,735 | -5.06 | -74.96% |
3 Years | 9.80 | 46.0977 | 1.325 | 6.76 | 279,937 | -8.11 | -82.76% |
5 Years | 10.50 | 46.0977 | 1.325 | 6.78 | 264,507 | -8.81 | -83.9% |
BioVie Description
BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |